Last reviewed · How we verify
NCT02671175: PMC
Post-discharge Malaria Chemoprevention(PMC) Study
Phase 3 trial testing dihydroartemisinin-piperaquine in Malaria in 1,049 participants. Completed in 12 December 2018.
24 October 2018
Quick facts
| Lead sponsor | Liverpool School of Tropical Medicine |
|---|---|
| Phase | Phase 3 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | prevention |
| Enrollment | 1,049 |
| Start date | 20 May 2016 |
| Primary completion | 24 October 2018 |
| Estimated completion | 12 December 2018 |
| Sites | 9 locations across Kenya, Uganda |
Drugs / interventions tested
- dihydroartemisinin-piperaquine
- dihydroartemisinin-piperaquine placebo
Conditions studied
- Malaria — all drugs for Malaria →
- Severe Anemia — all drugs for Severe Anemia →
Sponsor
Liverpool School of Tropical Medicine
Who can join
Under 60 Months, any sex, with Malaria or Severe Anemia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study evaluates the efficacy and safety of 3 months of malaria chemoprevention post-discharge using dihydroartemisinin piperaquine (DHA-P) in children under 5 years of age admitted with severe anemia. One half will receive monthly DHA-P and the other half placebo.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Malaria Chemoprevention in the Postdischarge Management of Severe Anemia.
Kwambai TK, Dhabangi A, Idro R, Opoka R, et al · · 2020 · cited 59× · PMID 33264546 · DOI 10.1056/nejmoa2002820 -
Malaria chemoprevention with monthly dihydroartemisinin-piperaquine for the post-discharge management of severe anaemia in children aged less than 5 years in Uganda and Kenya: study protocol for a multi-centre, two-arm, randomised, placebo-controlled, superiority trial.
Kwambai TK, Dhabangi A, Idro R, Opoka R, et al · · 2018 · cited 17× · PMID 30400934 · DOI 10.1186/s13063-018-2972-1 -
Risk factors for recurrent severe anemia among previously transfused children in Uganda: an age-matched case-control study.
Dhabangi A, Idro R, John CC, Dzik WH, et al · · 2019 · cited 9× · PMID 30658602 · DOI 10.1186/s12887-019-1398-6 -
Community perceptions of paediatric severe anaemia in Uganda.
Dhabangi A, Idro R, John CC, Dzik WH, et al · · 2019 · cited 9× · PMID 30605461 · DOI 10.1371/journal.pone.0209476
Verify or expand the search:
- PubMed search for NCT02671175
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of dihydroartemisinin-piperaquine
Trials testing the same drug.
- NCT07246525 — Intermittent Preventive Treatment of Malaria in School-age Children to Decrease Community Transmission · Phase 4 · not yet recruiting
- NCT05323721 — Effectiveness and Chemoprevention Efficacy of Implementing Seasonal Malaria Chemoprevention in Karamoja Region, Uganda · Phase 4 · unknown
- NCT03208179 — Improving PRegnancy Outcomes With Intermittent preVEntive Treatment in Africa · Phase 3 · completed
- NCT03009526 — Efficacy and Safety of IPTp-DP Versus IPTp-SP in Malawi · Phase 3 · completed
- NCT02878200 — RHOST-cRCT, Reactive Household-based Self-administered Treatment Against Residual Malaria Transmission · NA · completed
Other recruiting trials for Malaria
Currently open trials in the same condition.
- NCT07358910 — Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective · recruiting
- NCT07036159 — A Study to Assess the Safety and Immunogenicity of a Vaccine Against Malaria in Healthy Children Aged 5-60 Months · Phase 2 · recruiting
- NCT06735209 — First-in-Human PfSPZ-LARC2 Vaccination/CHMI · Phase 1 · active not recruiting
- NCT06854042 — A Study of Oral E1018 in Healthy Adult Participants · Phase 1 · recruiting
- NCT06607003 — Induced Blood-Stage Malaria in Healthy Malaria-Naive Adults to Assess the Safety and Infectivity of Plasmodium Vivax Cha · Phase 1 · recruiting
Other Liverpool School of Tropical Medicine trials
Trials by the same sponsor.
- NCT07403318 — Mobile Health Supported Self-care Among Tertiary Education Students in Zimbabwe · NA · not yet recruiting
- NCT06944275 — Characterising the Loss of Haemostasis in Haemorrhagic Fever With Renal Syndrome · not yet recruiting
- NCT07504926 — A Randomised Feasibility Study of CPAP in Large Airway Collapse · NA · not yet recruiting
- NCT07248423 — Start Taking Action for Tuberculosis in Kids · NA · not yet recruiting
- NCT07420881 — Start4All - Start Taking Action for TB Diagnosis (DARE-TB) · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02671175 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Liverpool School of Tropical Medicine
- Last refreshed: 4 June 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02671175.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing